ArticleFrontiers in pharmacology2022
Gentiopicroside Ameliorates Diabetic Renal Tubulointerstitial Fibrosis
Article in Frontiers in pharmacology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 38 citations in OpenAlex.
- Gentiopicroside inhibits HMGCR/NF-κB pathway to alleviate renal fibrosis.BMC complementary medicine and therapies · 2026Article
- Traditional Chinese medicine in diabetes management: a comprehensive review of mechanisms and therapeutic potential.Frontiers in endocrinology · 2026Review
- Gentiopicroside alleviates type 2 diabetes mellitus by attenuating oxidative stress and reshaping gut microbiota in high-fat diet and streptozotocin-induced mice.Frontiers in nutrition · 2026Article
- Dihydroartemisinin ameliorates renal tubulointerstitial fibrosis in diabetic nephropathy via restoring mitochondrial function via HIF-1α/HO-1 pathway.Scientific reports · 2025Article
- Gentiopicroside alleviates neuroinflammation in Parkinson's disease by mediating microglial pyroptosis via the NF-κB/NLRP3/GSDMD pathway.Histology and histopathology · 2025Article
- Candesartan Mitigates Perioperative Neurocognitive Disorders by Modulating Hypertension-Linked Neuroinflammatory Factor.Neurochemical research · 2025Article
- Mesenchymal Stem Cells Mediated Suppression of GREM2 Inhibits Renal Epithelial-Mesenchymal Transition and Attenuates the Progression of Diabetic Kidney Disease.International journal of stem cells · 2025Article
- Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.Chinese journal of integrative medicine · 2025Review
- G protein-coupled receptor 107 deficiency promotes development of diabetic nephropathy.Molecular biomedicine · 2025Article
- Therapeutic efficacy and mechanisms of gentiopicroside in various diseases.Frontiers in pharmacology · 2025Review
- The Therapeutic Effect and Mechanism of Traditional Chinese Medicine in Type 2 Diabetes Mellitus and Its Complications.Diabetes, metabolic syndrome and obesity : targets and therapy · 2025Review
- Pulmonary hypertension and chronic kidney disease: prevalence, pathophysiology and outcomes.Nature reviews. Nephrology · 2024Review
- Article
- Review
- Study of the mechanism by gentiopicroside protects against skin fibroblast glycation damage via the RAGE pathway.Scientific reports · 2024Article
- Regulatory mechanisms of Gentiopicroside on human diseases: a brief review.Naunyn-Schmiedeberg's archives of pharmacology · 2024Review
- Diosmin ameliorates renal fibrosis through inhibition of inflammation by regulating SIRT3-mediated NF-κB p65 nuclear translocation.BMC complementary medicine and therapies · 2024Article
- Gentiopicroside injection promotes the healing of pressure injury wounds by upregulating the expression of bFGFR1.Revista da Escola de Enfermagem da U S P · 2024Article
- Molecular mechanisms and therapeutic potential of natural flavonoids in diabetic nephropathy: Modulation of intracellular developmental signaling pathways.Current research in pharmacology and drug discovery · 2024Review
- Gentiopicroside-An Insight into Its Pharmacological Significance and Future Perspectives.Cells · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Renal tubulointerstitial fibrosis (TIF), characterized by epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells, is the typical pathological alteration in diabetic nephropathy. Gentiopicroside (GPS), a natural compound with anti-inflammatory activity, has been demonstrated to alleviate glomerulosclerosis, whereas whether GPS inhibits TIF
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.